Hemostatic materials
A safe and effective hemostatic material is provided. A hemostatic material comprising as an effective ingredient thrombin and fibrinogen characterized in that a bioabsorbable synthetic nonwoven fabric is used as a supporting material. The use of the hemostatic material of the present invention allows for quick and thorough hemostasis for both projectile bleeding and exudative bleeding.
1 . A hemostatic material comprising as an effective ingredient thrombin and fibrinogen held on a supporting material consisting of a bioabsorbable synthetic nonwoven fabric.
2 . The hemostatic material according to claim 1 , wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.
3 . The hemostatic material according to claim 1 , wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.
4 . The hemostatic material according to claim 1 , wherein the bioabsorbable synthetic nonwoven fabric previously holds at least thrombin among thrombin and fibrinogen.
5 . The hemostatic material according to claim 1 , wherein said hemostatic material comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.
6 . The hemostatic material according to claim 1 , wherein thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.
7 - 13 . (canceled)
14 . A method of preparing a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient, comprising the steps of immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and lyophilizing the obtained nonwoven fabric.
15 . The method according to claim 14 , wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.
16 . The method according to claim 14 , wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.
17 . The method according to any claim 14 , wherein said hemostatic material comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.
18 . The method according to claim 17 , wherein said calcium chloride is fixed to the bioabsorbable synthetic nonwoven fabric together with thrombin.
19 . The method according to claim 17 , wherein said Factor XIII is added to fibrinogen.
20 . The method according to claim 14 , wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.
21 . A hemostatic kit comprising a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient, and a container comprising fibrinogen as an effective ingredient.
22 . The hemostatic kit according to claim 21 , wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.
23 . The hemostatic kit according to claim 21 , wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.
24 . The hemostatic kit according to claim 21 , wherein said hemostatic kit comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.
25 . The hemostatic kit according to claim 24 , wherein said calcium chloride is added to the bioabsorbable synthetic nonwoven fabric as an additive for thrombin.
26 . The hemostatic kit according to claim 24 , wherein said Factor XIII is included in a container comprising fibrinogen.
27 . The hemostatic kit according to claim 21 , wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.
28 . The hemostatic kit according to claim 21 , wherein said bioabsorbable synthetic nonwoven fabric holding thrombin is prepared by the steps of immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained nonwoven fabric.
29 . A hemostatic kit comprising a bioabsorbable synthetic nonwoven fabric as a substrate, a container comprising thrombin as an effective ingredient and a container comprising fibrinogen as an effective ingredient.
30 . The hemostatic kit according to claim 29 , wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.
31 . The hemostatic kit according to claim 29 , wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.
32 . The hemostatic kit according to claim 29 , wherein said hemostatic kit comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.
33 . The hemostatic kit according to claim 32 , wherein said Factor XIII is included in a container comprising fibrinogen.
34 . The hemostatic kit according to claim 29 , wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.